相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies
Sharon Elad et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Immune-checkpoint inhibitors: long-term implications of toxicity
Douglas B. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
Victor Albarran et al.
FRONTIERS IN PHARMACOLOGY (2022)
mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment
Sahar Mafi et al.
FRONTIERS IN IMMUNOLOGY (2022)
Molecular Pathways and Mechanisms of BRAF in Cancer Therapy
Poulikos I. Poulikakos et al.
CLINICAL CANCER RESEARCH (2022)
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
Ryan J. Sullivan et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
Sicca syndrome associated with immune checkpoint inhibitor therapy
Jack A. Harris et al.
ORAL DISEASES (2022)
Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
Brittany A. Klein et al.
ORAL DISEASES (2022)
Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events A Systematic Review and Meta-analysis
Muhammad Zain Farooq et al.
JAMA NETWORK OPEN (2022)
The blue palate-A case series of imatinib-related oral pigmentation and literature review
Christopher C. Donnell et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2021)
Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer
Jake S. Jacob et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019
Yuanming Xu et al.
CANCER (2021)
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Amanda C. Guidon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending
Ariadna Ortiz Brugues et al.
ONCOLOGIST (2020)
Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series
Muhammad Ali Shazib et al.
ORAL DISEASES (2020)
A review of cancer immunotherapy toxicity
Lucy Boyce Kennedy et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
An update on pharmacotherapies in active development for the management of cancer regimen-associated oral mucositis
Alessandro Villa et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion
R. Dummer et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos-Casals et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Is oral dysaesthesia a somatic symptom disorder?
Kenelm Chun Lam Kwong et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2020)
Research progress of mTOR inhibitors
Yifan Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Hedgehog Signaling Regulates Taste Organs and Oral Sensation: Distinctive Roles in the Epithelium, Stroma, and Innervation
Charlotte M. Mistretta et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review
Sicilia Rezende Oliveira et al.
CLINICAL ORAL INVESTIGATIONS (2019)
Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy
Blake M. Warner et al.
ONCOLOGIST (2019)
Molecular targeted therapy: Treating cancer with specificity
Yeuan Ting Lee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients
L. Lo Muzio et al.
ORAL DISEASES (2018)
Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients
Claudia Arena et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Judith A. Seidel et al.
FRONTIERS IN ONCOLOGY (2018)
Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
Mario Lacouture et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
N. Basset-Seguin et al.
EUROPEAN JOURNAL OF CANCER (2017)
On the pathogenesis of mTOR inhibitor-associated stomatitis (mIAS)studies using an organotypic model of the oral mucosa
S. Sonis et al.
ORAL DISEASES (2017)
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
Emmanuelle Vigarios et al.
SUPPORTIVE CARE IN CANCER (2017)
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Vivek Kumar et al.
FRONTIERS IN PHARMACOLOGY (2017)
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Clemence Granier et al.
ESMO OPEN (2017)
Immunotherapy in Peripheral Neuropathies
Jean-Marc Leger et al.
NEUROTHERAPEUTICS (2016)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
Mario E. Lacouture et al.
ONCOLOGIST (2016)
Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice
Douglas E. Peterson et al.
CANCER MEDICINE (2016)
Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-upaEuro
D. E. Peterson et al.
ANNALS OF ONCOLOGY (2015)
Mammalian Target of Rapamycin Inhibitor-Associated Stomatitis in Hematopoietic Stem Cell Transplantation Patients Receiving Sirolimus Prophylaxis for Graft-versus-Host Disease
Alessandro Villa et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors
E. Vigarios et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials
Marco Miroddi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Mucositis: pathobiology and management
Alessandro Villa et al.
CURRENT OPINION IN ONCOLOGY (2015)
Imatinib-induced dental hyperpigmentation in chronic myeloid leukemia in an adult female
Prabhat Agrawal et al.
INDIAN JOURNAL OF PHARMACOLOGY (2015)
Hedgehog pathway blockade with the cancer drug LDE225 disrupts taste organs and taste sensation
Archana Kumari et al.
JOURNAL OF NEUROPHYSIOLOGY (2015)
Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer
Tomonobu Koizumi et al.
LUNG CANCER (2015)
Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors
Anna Yuan et al.
ORAL ONCOLOGY (2015)
Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors forMetastatic Melanoma
Giuliana Carlos et al.
JAMA DERMATOLOGY (2015)
Lichenoid Mucosal Reaction to Rituximab
Michal Kuten-Shorrer et al.
ONCOLOGIST (2014)
Defining the Role of Sirolimus in the Management of Graft-versus-Host Disease: From Prophylaxis to Treatment
Ahmed Abouelnasr et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Mammalian target of rapamycin inhibitor-associated stomatitis
Christine B. Boers-Doets et al.
FUTURE ONCOLOGY (2013)
Geographic Tongue Induced by Angiogenesis Inhibitors
Thomas Hubiche et al.
ONCOLOGIST (2013)
A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients
Fabiana Martins et al.
ORAL ONCOLOGY (2013)
Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
Suzanne George et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Characteristics of Oral Mucosal Events Related to Bevacizumab Treatment
Igor T. Gavrilovic et al.
ONCOLOGIST (2012)
Mucosal Pigmentation Caused by Imatinib: Report of Three Cases
Chia-Cheng Li et al.
HEAD & NECK PATHOLOGY (2012)
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy
Camillo Porta et al.
BMC CANCER (2011)
Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities
Christian Kollmannsberger et al.
ONCOLOGIST (2011)
Clinical presentation and management of mTOR inhibitor-associated stomatitis
Marcio Augusto de Oliveira et al.
ORAL ONCOLOGY (2011)
Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact
F. Elice et al.
THROMBOSIS RESEARCH (2010)
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib
W. J. Lee et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
Increased Risk of High-Grade Dermatologic Toxicities With Radiation Plus Epidermal Growth Factor Receptor Inhibitor Therapy
Ajay Tejwani et al.
CANCER (2009)
Imatinib-associated hyperpigmentation, a side effect that should be recognized
T. Mcpherson et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2009)
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
Youjin Je et al.
LANCET ONCOLOGY (2009)
Adverse effects of anticancer agents that target the VEGF pathway
Helen X. Chen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Skin and oral lesions associated to imatinib mesylate therapy
Fernanda Goncalves Basso et al.
SUPPORTIVE CARE IN CANCER (2009)
Sunitinib: A cause of bullous palntoplantar erythrodysesthesia, periungual erythema, and mucositis
Pitiporn Suwattee et al.
ARCHIVES OF DERMATOLOGY (2008)
Defects in skin γδ T cell function contribute to delayed wound repair in rapamycin-treated mice
Robyn E. Mills et al.
JOURNAL OF IMMUNOLOGY (2008)
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib
C. Porta et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2007)
Targeted therapy for metastatic renal cell carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Cutaneous side-effects of kinase inhibitors and blocking antibodies
C Robert et al.
LANCET ONCOLOGY (2005)
Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate
B Arora et al.
ANNALS OF ONCOLOGY (2004)
Current and future immunosuppressive strategies in renal transplantation
KL Hardinger et al.
PHARMACOTHERAPY (2004)
分享论文
